Penny Stocks To Follow Now – February 18th

Rackspace Technology, BigBear.ai, and Recursion Pharmaceuticals are the three Penny stocks to watch today, according to MarketBeat’s stock screener tool. Penny stocks are low-priced shares of typically small or thinly traded companies, commonly defined by the SEC as stocks that trade for less than $5 per share and often quoted over-the-counter or on smaller exchanges. They usually have low liquidity, wide bid–ask spreads and high volatility, making them high-risk investments with greater potential for fraud and large percentage gains or losses. These companies had the highest dollar trading volume of any Penny stocks within the last several days.

Rackspace Technology (RXT)

Rackspace Technology, Inc. operates as a multi cloud technology services company in the Americas, Europe, the Middle East, Africa, and The Asia-Pacific region. It operates through three segments: Multicloud Services, Apps & Cross Platform, and OpenStack Public Cloud. The company provides public and private cloud managed services, which allow customers to determine, manage, and optimize the right infrastructure, platforms, and services; professional services related to designing and building multi cloud solutions and cloud-native applications; and managed hosting and colocation services.

BigBear.ai (BBAI)

BigBear.ai Holdings, Inc. provides artificial intelligence-powered decision intelligence solutions. It offers national security, supply chain management, and digital identity and biometrics solutions. The company also provides data ingestion, data enrichment, data processing, artificial intelligence, machine learning, predictive analytics, and predictive visualization solutions and services.

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.